Other languages Karyopharm Therapeutics Inc.

Equities

KPTI

US48576U1060

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-22 pm EDT			5-day change	1st Jan Change
1.13 ^USD	-3.42%		-2.16%	+30.64%

Mar. 13	Transcript : Karyopharm Therapeutics Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 09:00 AM
Feb. 29	Transcript : Karyopharm Therapeutics Inc., Q4 2023 Earnings Call, Feb 29, 2024

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Karyopharm Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 29
Karyopharm Therapeutics Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 29
Karyopharm Therapeutics Inc. Provides Earnings Guidance for the Year 2024	Feb. 29
Karyopharm Therapeutics Inc. Provides Preliminary Unaudited Earnings Guidance for the Fourth Quarter and Full Year 2023	Jan. 08
Karyopharm Therapeutics Says Phase 1 Study of Myelofibrosis Treatment Showed Spleen Volume Reduction Durability	Dec. 11
Karyopharm Therapeutics Inc. Shares Data at ASH 2023 Showing Strong SVR and TSS Durability Observed from Phase 1 Study of Selinexor 60mg and Ruxolitinib in JAK Inhibitor (JAKi-Naive Myelofib) Patients	Dec. 10
Karyopharm Therapeutics Inc. Announces Resignation of Peter K Honig as Member of the Board of Directors	Dec. 08
Karyopharm Therapeutics Inc. Announces Presentations at the 65th American Society of Hematology Annual Meeting and Exposition	Nov. 02
Karyopharm Therapeutics Inc. Reiterates Revenue Guidance for the Full Year 2023	Nov. 02
Karyopharm Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 02
Karyopharm, Bristol-Myers Squibb to Assess Mezigdomide With Selinexor for Relapsed, Refractory Multiple Myeloma	23-10-30
Karyopharm Therapeutics Inc. Announces Clinical Trial Collaboration with Bristol Myers Squibb to Evaluate Novel CELMoD?? Agent CC-92480 Mezigdomide in Combination with Selinexor in Patients with Relapsed/Refractory Multiple Myeloma	23-10-30
Karyopharm Therapeutics Inc. Appoints Zhen Su to Its Board of Directors	23-09-01
Karyopharm Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-02
Karyopharm Therapeutics Inc. Announces Earnings Guidance for the Year 2023	23-08-02
Karyopharm Therapeutics Inc. Announces Presentation of Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer	23-07-25
Top Premarket Gainers	23-07-18
Karyopharm Therapeutics Gets FDA Fast Track Label for Selinexor For Myelofibrosis Treatment	23-07-17
Karyopharm Therapeutics Inc. Initiates Pivotal Phase 3 Clinical Trial (XPORT-MF-034) to Assess Efficacy and Safety of Once-Weekly Selinexor 60Mg in Combination with Ruxolitinib in JAKi-NaÃ¯ve Patients with Myelofibrosis	23-06-28
Karyopharm Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-04

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Karyopharm Therapeutics Inc.

Equities

KPTI

US48576U1060

Other languages

Filters